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Abstract
Activation of peroxisome proliferator–activated
receptor-; (PPAR-;) results in inhibition of tumor
growth in various types of cancers, but the mecha-
nism(s) by which PPAR-; induces growth arrest has
not been completely defined. In a recent study, we
demonstrated that treatment of A549 (human non small
cell lung cancer cell line) tumor-bearing SCIDmice with
PPAR-; ligands troglitazone (Tro) and pioglitazone
significantly inhibits primary tumor growth. In this
study, immunohistochemical analysis of Tro-treated
and Pio-treated tumors with factor VIII antibody
revealed a significant reduction in blood vessel density
compared to tumors in control animals, suggesting
inhibition of angiogenesis. Further analysis showed
that treatment of A549 cells in vitrowith Tro or transient
transfection of A549 cells with constitutively active
PPAR-; (VP16–PPAR-;) construct blocked the pro-
duction of the angiogenic ELR +CXC chemokines IL-8
(CXCL8), ENA-78 (CXCL5), and Gro-A (CXCL1). Simi-
larly, an inhibitor of NF-KB activation (PDTC) also
blocked CXCL8, CXCL5, and CXCL1 production, con-
sistent with their NF-KB–dependent regulation. Con-
ditioned media from A549 cells induce human
microvascular endothelial cell (HMVEC) chemotaxis.
However, conditioned media from Tro-treated A549
cells induced significantly less HMVEC chemotaxis
compared to untreated A549 cells. Furthermore,
PPAR-; activation inhibited NF-KB transcriptional
activity, as assessed by TransAM reporter gene assay.
Collectively, our data suggest that PPAR-; ligands
can inhibit tumor-associated angiogenesis by blocking
the production of ELR+CXC chemokines, which is
mediated through antagonizing NF-KB activation.
These antiangiogenic effects likely contribute to the
inhibition of primary tumor growth by PPAR-; ligands.
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Introduction
Peroxisome proliferator–activated receptors (PPARs) are a
family of ligand-activated transcription factors consisting of
three isotypes: PPAR-a, PPAR-b/y, and PPAR-g. PPARs serve
as intracellular sensors to fatty acids and fatty acid deriva-
tives, which in turn act as endogeneous ligands to PPARs,
leading to transcriptional regulation of pathways involved in
lipid and glucose metabolism. PPARs heterodimerize with
retinoid X receptors (RXRs), forming a complex that regulates
target gene expression. Ligand binding results in a conforma-
tional change in the receptor that permits the dissociation of
corepressors and concomitant association of coactivators.
The heterodimer–coactivator complex binds to specific re-
sponse elements (PPREs) in the promoter regions of target
genes to regulate transcription. PPAR-g is highly expressed in
adipose tissues and is a master regulator of adipocyte differ-
entiation [1,2]. In humans, PPAR-g is expressed in multiple
other tissues, including breast, colon, prostate, lung, placenta,
and pituitary tissues [3–6]. PPAR-g is a molecular target for
thiazolidinediones (TZDs), a class of insulin-sensitizing agents
such as troglitazone (Tro), rosiglitazone, and pioglitazone
(Pio). PPAR-g activation is antiproliferative by virtue of its
differentiation-promoting effects. For example, ligands acti-
vating PPAR-g were effective in arresting the growth of dedif-
ferentiated tumor cells in multiple tumor types [3,5,7–9],
making PPAR-g a potential therapeutic target for cancer. In
a recent study, we have shown that PPAR-g ligands Tro and
Pio inhibit the growth of NSCLC cells in vitro and in vivo [8]. We
have also shown that PPAR-g ligands promote differentiation
of tumor cells and block spontaneous metastasis in a xeno-
graft model [8]. However, the mechanisms by which these
ligands inhibit tumor growth and metastasis have not been
completely defined.
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Angiogenesis is an essential component of tumor pro-
gression and metastasis. A variety of factors have been
found to modulate angiogenesis [10]. Net tumor-induced
angiogenesis is believed to be due to an imbalance in
the expression of angiogenic factors relative to angiostatic
factors [11]. Among the factors that can regulate angiogen-
esis is a unique family of 8- to 10-kDa molecules known as
CXC chemokines. These molecules are initially character-
ized as a family of neutrophil chemotactic factors during
inflammation. However, their angiogenic activity is distinct
from their ability to induce inflammation. The CXC chemo-
kine family consists of a number of structurally related
peptides that either promote or inhibit angiogenesis. All of
the angiogenic members of CXC chemokine family such as
IL-8 (CXCL8), ENA78 (CXCL5), and Gro-a (CXCL1) contain
a three–amino-acid motif of glutamic acid– leucine–arginine
(ELR motif) residues, which precedes the first cysteine
residue in their CXC motif present in their amino terminus
[12]. The angiogenic activity of ELR+CXC chemokines is
mediated through the CXC motif ligand receptor 2 (CXCR2)
[13]. CXCR2 has been shown to bind all ELR+CXC chemo-
kines with high affinity [14–17]. Previous studies have
established the role of these ELR+CXC chemokines in
human NSCLC [10]. The transcription factor nuclear factor-
kappa B (NF-nB) regulates the expression of several genes
involved in inflammation, including that of CXC chemokines
[18–22]. Promoter regions of CXC chemokine genes contain
NF-nB–binding sites. The expression of CXCL8, CXCL5,
and CXCL1 is upregulated in response to different stimuli in
an NF-nB–dependent fashion [18–21,23]. PPAR-g, in addi-
tion to its differentiation-promoting and antiproliferative
effects, has been described as a negative regulator of
macrophage function [24]. It suppresses the production of
inflammatory cytokines/chemokines, in part by antagonizing
activities of transcription factors AP-1, STAT, and NF-nB
[25]. In the present study, we investigated the role of PPAR-g
in regulating ELR+CXC chemokine expression from tumor
cells, the effect of such regulation on endothelial cell func-
tion, and its implications for tumor-associated angiogenesis
and primary tumor growth in NSCLC.
Materials and Methods
Cell Culture
The A549 human lung adenocarcinoma cell line was
obtained from the American Type Culture Collection (Rock-
ville, MD) and maintained in RPMI 1640 medium with gluta-
mine, supplemented with 10% FBS and antibiotics penicillin
and streptomycin. Human microvascular endothelial cells
(HMVEC-1) kindly provided by Dr. Edwin Ades and Mr.
Francisco J. Candal (Center for Disease Control, National
Center for Infectious Diseases, Atlanta, GA) and Dr. Thomas
Lawley (Emory University, Atlanta, GA), were maintained in
MDCB131 medium (GibcoBRL, Grand Island, NY) to which
fetal calf serum (FCS) (10%), 100 U/ml penicillin, 100 mg/ml
streptomycin, 1% L-glutamine, 10 ng/ml endothelial growth
factor (EGF), and 1 mg/ml hydrocortisone had been added.
Media were changed in all cell lines every 48 to 72 hours. All
cell lines were incubated at 37jC with 5% CO2.
Tumor Xenografts in SCID Mice
Six-week–old CB17-SCID mice were subcutaneously
injected with A549 cells on either side of the dorsal flank.
Six mice per group were treated once daily by oral gavage for
8 weeks with Tro (200 mg/kg) or Pio (25 mg/kg) or placebo,
formulated by suspending drugs in an aqueous solution of
2% carboxymethylcellulose and 0.2% Tween 20 and then
sonicating for 5 minutes. After 8 weeks, animals were
sacrificed and tumors were dissected from the mice, fixed
in formalin, and embedded in paraffin for thin sectioning.
Quantification of Vessel Density in Tumors
Quantitation of vessel density was performed using the
method described previously [26,27]. In brief, tissue sec-
tions from paraffin-embedded tumors of control-treated, Tro-
treated (200 mg/kg), and Pio-treated (25 mg/kg) A549
xenografts were dewaxed and rehydrated. Slides were
stained for endothelial cells using antibody to factor VIII–
related antigen conjugated to horseradish peroxidase (EP-
OS staining reagent; DAKO Corporation, Carpinteria, CA)
for 1 hour at room temperature. 3,3V-Diaminobenzidine
(Vector Laboratories, Burlingame, CA) was used for locali-
zation of factor VIII– related antigen. After optimal color
development, sections were immersed in water and cover-
slipped. Tissue sections were scanned at low magnification
(40) to identify vascular hot spots. Areas of greatest
vessel density were then examined under higher magnifica-
tion (200) and counted. Any distinct area of positive
staining for factor VIII–related antigen was counted as a
single vessel. Two investigators, blinded to the identity of the
specimen, independently scored sections from each tumor.
The average of three high-power fields (HPFs) per section
was taken, and the results for each treatment group were
expressed as the mean ± SE, representing a minimum of
12 tumors per group.
ELR+CXC Chemokine ELISA
ELR+CXC chemokines [IL-8 (CXCL8), ENA-78 (CXCL5),
and GRO- (CXCL1)] were quantitated by a double-ligand
method described previously [28]. In brief, flat-bottom 96-
well microtiter plates (Immuno Plate F96; Nunc, Rochester,
NY) were coated with the appropriate purified Abs overnight
at 4jC and were then washed three times with PBS with
0.05% Tween 20 (washing buffer). Nonspecific binding sites
were blocked with PBS and 2% BSA. After washing three
times, samples (neat and 1:10 dilution) and standards were
added as 50-ml aliquots and incubated at 37jC. Plates were
washed three times and incubated with the respective bio-
tinylated Ab at 37jC. Plates were again washed three times
and incubated with polyperoxidase–avidin substrate (Endo-
gen, Woburn, MA) at 37jC. Subsequently, plates were
incubated with the peroxidase substrate (DAKO Corpora-
tion) at room temperature to the desired extinction. The
reaction was terminated with 0.5 M H2SO4. Plates were read
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at 490 nm in an ELISA reader. Standards were prepared as
1/2 log dilutions of purified recombinant Ab, from 100 to
0.001 ng/ml per well.
Endothelial Cell Chemotaxis Assay
Chemotaxis membrane filters (5.0 mm pore size)
(Osmonics, Livermore, CA) were prepared by bathing in
2.8% glacial acetic acid for 24 hours, followed by two 1-hour
rinses in deionized, distilled water. The filters were then
transferred to a 0.01% gelatin bath to soak for 24 hours.
Filters were dried under a laminar flow hood, and stored at
room temperature for up to 1 month. Endothelial cell che-
motaxis assays were performed in 12-well blind well chemo-
taxis chambers (Neuro Probe, Gaithersburg, MD). Briefly,
human endothelial cells (HMEC-1) were suspended at a
concentration of 106 cells/ml in serum-free media with
0.1% BSA. Endothelial cells were placed into each of the
bottom wells (165 ml). Membranes were placed over the
wells, the gasket applied, and the chambers sealed. Cham-
bers were inverted and incubated at 37jC with 5% CO2 for
1 hour to allow for endothelial cell adherence to the mem-
brane. Chambers were then reinverted and the test media
were placed in the upper well (116 ml). Chambers were
reincubated for 2 hours. Membranes were then scraped to
remove any unmigrated endothelial cells from the lower
chamber, fixed in methanol, and stained with a modified
Wright-Giemsa stain, and cells that had migrated through the
membrane were counted in 5 HPF (200). Results were
expressed as the mean number of endothelial cells that had
migrated per HPF ± SE. Each sample was assessed in
triplicate. Experiments were performed at least three times.
Each experiment was accompanied by a positive control
(VEGF 100 ng/ml) and a negative control (nonconditioned
media) to account for variable chemotaxis from one assay
to the next.
Transient Transfection
The constitutively active VP16–PPAR-g fusion cDNAwas
obtained from Dr. Mitchel Lazar (University of Pennsylvania,
Philadelphia, PA) and was subcloned into mammalian ex-
pression vector pcDNA under the control of CMV promoter.
A549 cells were seeded in six-well plates and allowed to
reach 60% to 70% confluence. The cells were transfected in
the absence of serum with 2 mg/well of either VP16–PPAR-g
construct or the empty vector. After 4 hours of transfection,
cells were washed and grown in the presence of 20% serum.
After 24 hours, cells were treated with TNF-a in the absence
of serum. Conditioned media were collected after 24 hours
of TNF-a treatment for measuring chemokine levels.
Cell Proliferation
Cell proliferation was measured using Promega’s (Mad-
ison, WI) aqueous one-solution cell proliferation assay
according to the manufacturer’s protocol. It is based on the
cellular conversion of a tetrazolium salt into a soluble for-
mazon product as a measure of proliferation. In brief, 2000
cells were plated in each well of a 96-well plate in RPMI 1640
medium with 10% serum. After 24 hours, cells were treated
with various concentrations of PPAR-g agonists. After
48 hours of incubation with agonists, the aqueous one-
solution reagent was added and incubated for 2 to 3 hours.
The intensity of the color was measured at 490 nm using a
96-well plate reader.
NF-nB Activation Assay
NF-nB activation was assayed using Active Motif’s (Carls-
bad, CA) ELISA-based transactivation TransAM kit following
the manufacturer’s protocol. The NF-nB TransAM kit con-
tains a 96-well plate with immobilized oligonucleotides
encoding an NF-nB consensus site (5V-GGGACTTTCC- 3V).
The active form of NF-nB contained in the cell extract
specifically binds to this oligonucleotide. The primary anti-
body used to detect NF-nB recognizes an epitope on p65 that
is accessible only when NF-nB is activated and bound to its
target DNA. A horseradish peroxidase (HRP)–conjugated
secondary antibody provides a sensitive colorimetric readout
that is quantified by a spectrophotometer at 450 nm with a
reference wavelength of 655 nm.
Statistical Analysis
For most of the analyses, unpaired t test was employed
to determine P values, unless otherwise specified.
Results
PPAR-g Activation Inhibits Angiogenesis in
A549 Xenografts
We have previously shown that PPAR-g ligands inhibit
the growth of NSCLC cells in vitro and in vivo in part by
promoting tumor cell differentiation [8]. A549 tumor-bearing
SCID mice, with six mice in each group, were treated with
either Tro (200 mg/kg) or Pio (25 mg/kg) or placebo once
daily by oral gavage for 8 weeks. A significant reduction
(65%) in primary tumor growth was observed at the end of
8 weeks [8]. Immunohistochemical analysis of primary
tumors with factor VIII antibody, an endothelial cell marker,
showed decreases in blood vessel density in Tro-treated and
Pio-treated tumors at 8 weeks, compared to the placebo-
treated control (Figure 1A). Quantitative analysis of blood
vessel density by manual counting of factor VIII–stained
vessels in the tumor sections revealed approximately 60%
decrease in vessel density in Tro-treated and Pio-treated
groups compared to the control (Figure 1B).
PPAR-g Activation Blocks Expression of Angiogenic
Chemokines in Tumor Cells
Tumor cells are one of the major sources for angiogenic
modulators during tumor progression, and CXC chemokines
expressed by tumor cells are believed to be attributed to
tumor-associated angiogenesis. Specifically, ELR+CXC
chemokines, including CXCL8, CXCL5, and CXCL1, medi-
ate both in vivo and in vitro angiogenic activities by directly
stimulating proliferation and migration of endothelial
cells [29–33]. A549 cells secrete significant amounts of
CXCL8, CXCL5, and CXCL1 constitutively, and increase
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the expression of chemokines on stimulation with TNF-a
(Figure 2A). The secreted levels of each chemokine were
assessed by the respective chemokine-specific ELISA in the
conditioned media collected from A549 cells. The condi-
tioned media were collected from A549 cells after 24 hours
of various treatments as indicated, in serum-free media.
Treatment of A549 cells with the PPAR-g agonist Tro
blocked constitutive and TNF-a induced expression of
CXCL8, CXCL5, and CXCL1 in a dose-dependent manner
(Figure 2, A–C). Of note, treatment of A549 cells with Tro for
24 hours at the concentrations used did not effect prolifera-
tion or apoptosis significantly, as assessed by MTT assay
and ssDNA ELISA, respectively [8]. Fusion of the potent viral
transcription factor VP16 with PPAR-g renders it constitu-
tively active in a ligand-independent fashion [34]. Transient
transfection of VP16–PPAR-g into A549 cells also blocked
CXCL8, CXCL5, and CXCL1 protein expression (Figure 2,
D–F ). This suggests that inhibition of CXC chemokine
expression by Tro is dependent on PPAR-g activation.
Inhibition of Angiogenic Chemokines Reduces Endothelial
Cell Chemotactic Activity by Tumor Cells
One of the key endothelial cell functions that contribute to
the progression of angiogenesis is endothelial cell migration.
ELR+CXC chemokines induce endothelial cell migration
through chemotactic signaling. To assess the effect of block-
ing ELR+CXC chemokine secretion by tumor cells on angio-
genesis, we assayed the conditioned media from Tro-treated
A549 cells for its ability to induce endothelial cell chemotaxis.
Conditioned media from unstimulated A549 cells induced
appreciable endothelial cell chemotaxis (Figure 3), which
was significantly reduced in the conditioned media from Tro-
treated A549 cells, consistent with the observed chemokine
expression under those conditions. TNF-a–stimulated con-
ditioned media induced significantly more endothelial cell
chemotactic activity compared to the conditioned media from
unstimulated cells. Importantly, Tro treatment also abolished
the TNF-a–induced endothelial cell chemotaxis in the A549
conditioned media.
As an important control, we found that Tro treatment did
not have any effect on the growth of HMVEC cells during the
(2-hour) course of the chemotaxis assay. However, long-
term treatment of up to 3 days with Tro inhibited HMVEC cell
growth (Figure 4). This suggests that CXCL8, CXCL5, and
CXCL1 secreted by A549 cells are important regulators of
endothelial cell chemotaxis, and that inhibiting the expres-
sion of these chemokines in tumor cells will attenuate
endothelial cell chemotaxis. In addition, Tro can also inhibit
endothelial cell growth directly on long-term exposure.
PPAR-g Activation Antagonizes NF-nB Activation
It is known from previous studies that expression of ELR+
CXC chemokines and angiogenesis can be regulated by
NF-nB activity [20]. It has also been shown that PPAR-g
agonists can antagonize NF-nB activation [24,25]. In the
present study, we sought to elucidate whether PPAR-g
Figure 1. Effect of PPAR-c ligands on tumor blood vessel density. (A) A representative photomicrograph (200) of factor VIII – stained sections of A549 tumors
grown in SCID mice treated with placebo, Tro (200 mg/kg), or Pio (25 mg/kg). (B) Vessel density was quantified by counting the number of factor VIII –positive
vessels per HPF (200) (see Materials and Methods section). Each column represents mean ± SE from at least three HPFs per tumor having 12 tumors in
each group.
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agonists can antagonize NF-nB activation, and, if so,
whether the expression of ELR+CXC chemokines is NF-
nB–dependent in NSCLC cells. Consistent with previous
studies, we observed that pharmacologic inhibition of NF-
nB activation by pyrrolidinecarbodithioic acid (PDTC) [35]
blocked the expression of all the three ELR+CXC chemo-
kines (Figure 5). Furthermore, the PPAR-g agonist Tro
inhibited both constitutive as well as TNF-a–induced NF-
nB activation in A549 cells in a dose-dependent manner,
as determined by ELISA-based transcriptional reporter as-
say. This suggests that modulation of NF-nB activity is
involved in PPAR-g ligand-induced inhibition of ELR+CXC
chemokine expression.
Discussion
Lung cancer is the leading cause of cancer-related death for
both men and women in the United States [36]. In most
cases, lung cancer patients are diagnosed with advanced
inoperable disease and left with the only option of systemic
chemotherapy. Unfortunately, conventional therapies may
have reached a ceiling of clinical impact as evidenced by
the 5-year survival rates of 14% and 5% for NSCLC and
SCLC, respectively. More innovative strategies and newer
therapeutic agents are urgently needed for the control of this
disease. Recent advances in cell and developmental biology
led to the identification of novel antitumor approaches with
potential therapeutic targets [37,38]. Because PPAR-g is
identified as a master regulator of adipocyte differentiation, it
is being evaluated as a therapeutic target for promoting
differentiation in dedifferentiated tumor cells. Ligands activat-
ing PPAR-g have been shown to induce differentiation and
inhibit tumor growth in multiple tumor types [3,5,7–9]. We and
others have shown that PPAR-g ligands can also inhibit the
growth of NSCLC cells both in vitro and in vivo [39,8].
However, the precise mechanisms with which these ligands
inhibit tumor growth are still not clear. In this study, we pres-
ent an additional mechanism that may, in part, contribute to
tumor growth inhibition achieved by PPAR-g ligands.
Angiogenesis is a rate-limiting step in tumor development.
Avascular tumors are limited in size by the diffusion distance
of oxygen, nutrients, and cellular waste through the intersti-
tium (approximately 100–200 mm). Although tumors often
Figure 2. Effect of PPAR-c activation on ELR+CXC chemokine expression. Chemokine expression was quantified in A549 conditioned media by using chemokine-
specific ELISA as described in Materials and Methods section after 24 hours of various treatments in the absence of serum. (A–C) CXCL5, CXCL8, and CXCL1
expression in conditioned media of unstimulated and TNF-a–stimulated (10 ng/ml) A549 cells in the presence and absence of PPAR-c ligand Tro (10 and 20 M).
(D–F) CXCL5, CXCL8, and CXCL1 expression in conditioned media of unstimulated and TNF-a–stimulated (10 ng/ml) A549 cells in the presence and absence of
transient VP16–PPAR-c expression. Each column represents the mean ± SE from three independent experiments in (A) – (C) and two independent experiments in
(D)– (F).
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co-opt the existing vasculature, an angiogenic switch (i.e.,
the production of factors that induce angiogenic sprouting of
the vasculature) is required for propagation, invasion, and
subsequent metastasis of the tumor. A variety of factors,
including ELR+CXC chemokines, are implicated in the
growth and maintenance of new vasculature serving the
tumor. In this study, we demonstrate the role of PPAR-g in
the regulation of ELR+CXC chemokine expression in
NSCLC cells.
Tumor cells are critical sources for the expression of
angiogenic modulators. They produce various factors in
response to different cues present within the tumor micro-
environment. Factors within this environment include growth
factors produced by macrophages and stromal cells, matrix
components, and hypoxia. Consistent with earlier studies,
A549 cells express and secrete significant quantities of
CXCL8, CXCL5, and CXCL1 constitutively. TNF-a is consid-
ered as a key angiogenic cytokine produced by macro-
phages due to its ability to induce angiogenic molecules
such as VEGF, FGF, and ELR+CXC chemokines in tumor
cells. Stimulation of A549 cells with exogenous TNF-a
induced significant levels of CXCL8, CXCL5, and CXCL1
expression. Previously, a number of studies have estab-
lished a central role of ELR+CXC chemokines in promoting
angiogenesis in many malignancies, including lung cancer,
glioblastoma, adrenocortical carcinoma, prostate carcinoma,
ovarian carcinoma, gastric carcinoma, and melanoma [10].
In a recent study, White et al. [40] measured levels of ELR+
CXC chemokines in human lung cancer specimens and
reported elevated levels in tumor tissues relative to normal
lung tissues. Elevated ELR+CXC chemokine levels strongly
correlated with higher tumor vascularity and with increased
risk of recurrence of lung cancer [40]. This suggests that
ELR+CXC chemokines play an essential role in angiogene-
sis in NSCLC. Given the critical role of ELR+CXC chemo-
kines in NSCLC, it is clear that the ability of PPAR-g ligands
to inhibit the expression of these chemokines by tumor cells
will impact on the angiogenic potential of tumors. As pre-
dicted, conditioned media from Tro-treated A549 cells
showed significant reduction in the ability to induce endothe-
lial cell chemotaxis in a dose-dependent manner. Further-
more, PPAR-g ligands also exerted direct growth-inhibitory
effects on endothelial cells—consistent with previous reports
[41] providing an additional mechanism whereby PPAR-g
can regulate angiogenic responses.
The transcription factor NF-nB plays an important role in
regulating inflammatory and immune responses in mamma-
lian systems. CXCL8, CXCL5, and CXCL1 chemokines have
NF-nB binding sites in their promoter elements [42,43]. In
conditions such as diabetic retinopathy and rheumatoid
arthritis, TNF-a was shown to induce angiogenic ELR+
CXC chemokines in a NF-nB–dependent manner [23]. Here
we show that pharmacologic inhibition of NF-nB blocks the
expression of CXCL8, CXCL5, and CXCL1 in A549 cells.
Furthermore, PPAR-g ligands inhibit constitutive as well as
TNF-a–induced transcriptional activation of NF-nB in A549
cells. This suggests that modulation of NF-nB activity is
involved in PPAR-g ligand-induced inhibition of ELR+CXC
chemokine expression. It has been proposed that PPAR-g
activation leads to consumption of transcriptional coactiva-
tors required for NF-nB activation by competitive recruitment,
thus resulting in inhibition of NF-nB activation [24]. However,
it has recently been shown that PPAR-g forms a complex
with the p65 subunit of NF-nB. As a result, the newly formed
complex is exported from the nucleus, leading to the atten-
uation of NF-nB–mediated gene expression [44]. The ability
of PPAR-g ligands to antagonize TNF-a–induced NF-nB
activation may have additional implications, including the
possibility of sensitizing tumor cells to TNF-a–mediated
apoptosis. Given the important role ELR+CXC chemokines
play in the modulation of angiogenesis in NSCLC and the
inhibition of ELR+CXC chemokine expression by PPAR-g
ligands in tumor cells, resulting in decreased ability of the
tumor cells to stimulate angiogenesis, it is likely that the
observed decrease in tumor vessel density by Tro or Pio
Figure 3. Endothelial cell chemotactic activity of A549 conditioned media
after treatment with PPAR-c ligand. Conditioned media from A549 cells were
collected after various treatments in the absence of serum as indicated after
24 hours and assayed for its ability to induce endothelial cell chemotactic
activity as described in Materials and Methods section. The number of cells
that migrated through the membrane was counted in 5 HPF (200). Results
were expressed as the mean number of endothelial cells that had migrated
per HPF ± SE from three independent experiments. Concentrations used are
10 and 20 M Tro, and 10 ng/ml TNF-a. Serum-free RPMI 1640 medium
alone was used as a negative control (Ctrl).
Figure 4. Effect of PPAR-c ligand on endothelial cell proliferation. Cell
proliferation was assayed by using CellTiter 96 Aqueous One Solution
assay kit after treating serum-stimulated HMVEC for 3 days with different
concentrations of Tro. Percent proliferation was calculated relative to the
rate of proliferation in untreated cells, using the mean from three indepen-
dent experiments.
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treatment is due to PPAR-g–mediated inhibition of expres-
sion of angiogenic chemokines. The overall inhibition of
tumor growth by Tro may be due to a combination of different
PPAR-g–dependent and PPAR-g–independent effects.
In summary, our data suggest that PPAR-g activation can
inhibit tumor-associated angiogenesis by blocking the ex-
pression of ELR+CXC chemokines, which is mediated
through NF-nB activation. These antiangiogenic effects likely
contribute to the inhibition of primary tumor growth achieved
by PPAR-g ligands.
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